Beranda › Rabdomiosarkoma
Uji klinis Rabdomiosarkoma yang merekrut di AS
26 studi untuk Rabdomiosarkoma merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX6 studi
- Memphis, TN6 studi
- Washington, DC5 studi
- Boston, MA4 studi
- Salt Lake City, UT4 studi
- Philadelphia, PA4 studi
- Seattle, WA3 studi
- Aurora, CO3 studi
- Birmingham, AL3 studi
- The Bronx, NY3 studi
- Dallas, TX3 studi
- Baltimore, MD3 studi
Berdasarkan negara bagian
- Alabama3 studi
- California7 studi
- Colorado3 studi
- Distrik Columbia4 studi
- Florida3 studi
- Maryland4 studi
- Massachusetts4 studi
- New York4 studi
- Ohio5 studi
- Pennsylvania5 studi
- Tennessee8 studi
- Texas9 studi
- Utah4 studi
- Washington3 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Menerima pesertaFase 1
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Menerima pesertaFase 1
24 Months – 18 Years · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Menerima pesertaFase 3
Hingga usia 50 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Menerima peserta
Semua usia · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Menerima pesertaFase 1
Usia 1 hingga 23 · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT07172958Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT04715191Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT05210374Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Menerima pesertaFase awal 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Menerima pesertaFase 1/2
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Menerima peserta
Hingga usia 39 · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06625190Familial Investigations of Childhood Cancer Predisposition
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Menerima pesertaFase 2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Menerima pesertaFase 1/2
6 Months – 30 Years · Semua jenis kelamin · Diperbarui 2 Jun 2026 · NCT04796012B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Menerima pesertaFase 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Menerima pesertaFase 1
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Menerima pesertaFase 2
Usia 1 hingga 50 · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Menerima pesertaFase 1/2
Usia 12 hingga 49 · Semua jenis kelamin · Diperbarui 19 Feb 2026 · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Menerima pesertaFase 1
Usia 1 hingga 26 · Semua jenis kelamin · Diperbarui 17 Feb 2026 · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Menerima pesertaFase 1
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 22 Jan 2026 · NCT04995003Molecular Analysis Of Solid Tumors
Menerima pesertaStudi observasional
Hingga usia 25 · Semua jenis kelamin · Diperbarui 12 Nov 2025 · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Menerima pesertaFase 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 3 Nov 2025 · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Menerima pesertaFase 1
7 Months – 21 Years · Semua jenis kelamin · Diperbarui 16 Okt 2025 · NCT02508038Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.